Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories (Dr. Reddy’s), together with its subsidiaries, has announced its intention to acquire the issued and outstanding shares of OctoPlus N.V. (OctoPlus), a service based specialty pharmaceutical company, through a public offer, for an offer price of euro 27.39 million cum dividend in cash, representing 100% of the issued and outstanding ordinary shares.

The offer price represents a premium of 30% over the closing price of OctoPlus as of the end of the day October 19, 2012. Besides, this deal will help expand the expertise and scientific capabilities of Dr. Reddy’s.

The pharma company currently holds an irrevocable commitment from shareholders representing over 50% of OctoPlus’s issued and outstanding shares. Further, the executive board and the supervisory board of OctoPlus have unanimously recommended the offer to the remaining shareholders.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.